Conclusion The prevalence of sarcopenia depends mostly on the diagnostic cut-off points of different criteria .
Preoperative sarcopenia is a risk factor for both long-term and short-term outcomes
Background The impact of sarcopenia on the outcome of gastrointestinal ( GI ) oncological patients is still controversial .
We aim to discuss the prevalence of sarcopenia and its relation to the oncological outcome .
Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
BACKGROUND & AIMS Profound weight loss and malnutrition subsequent to severe dysphagia and cancer cachexia are cardinal symptoms in oesophageal cancer ( OC ) . Low muscle mass/sarcopenia has been linked to toxicity during neo-adjuvant therapy in other cancers , with worser effects in sarcopenic obesity . In this study the association between sarcopenia and /or sarcopenic obesity and dose limiting toxicity ( DLT ) during cycle one chemotherapy in resectable OC patients was evaluated . METHODS Body composition was assessed from computed tomography scans of 72 consecutively diagnosed OC patients . Lean body mass and body fat mass were estimated . Patients were grouped as sarcopenic or non-sarcopenic based on pre-defined gender-specific cut-offs for sarcopenia , and as underweight/normal ( BMI < 25 ) or overweight/obese ( BMI ≥ 25 ) . Sarcopenic obesity was defined as sarcopenia combined with overweight and obesity . DLT was defined as temporary reduction/delay or permanent discontinuation of drugs due to adverse effects . Odds ratios for developing toxicity were ascertained using multiple logistic regression . RESULTS Of 72 patients , 85 % ( n = 61 ) were males . Sarcopenia and sarcopenic obesity were present in 31 ( 43 % ) and 10 ( 14 % ) , respectively , prior to chemotherapy . Sarcopenic patients had significantly lower adipose tissue index ( p = 0.02 ) compared to non-sarcopenic patients . Patients with DLT ( n = 24 ) had lower skeletal muscle mass ( p = 0.04 ) than those without DLT . Sarcopenic patients ( OR = 2.47 ; 95 % CI : 0.88 - 6.93 ) showed a trend towards increased DLT risk ( p < 0.10 ) . Logistic regression with BMI as an interaction term indicated higher DLT risk in sarcopenic patients with normal BMI ( OR = 1.60 ; 95 % CI 0.30 - 8.40 ) , but was non-significant . In the sarcopenic obese , risk of DLT increased significantly ( OR = 5.54 ; 95 % CI 1.12 - 27.44 ) . CONCLUSIONS Sarcopenic and sarcopenic obese OC patients may be at a higher risk for developing DLT during chemotherapy compared to non-sarcopenic OC patients
Conclusion The prevalence of sarcopenia depends mostly on the diagnostic cut-off points of different criteria .
Preoperative sarcopenia is a risk factor for both long-term and short-term outcomes
Background The impact of sarcopenia on the outcome of gastrointestinal ( GI ) oncological patients is still controversial .
We aim to discuss the prevalence of sarcopenia and its relation to the oncological outcome .